Study #2021-1077
A Phase 2 Study To Assess The Effect Of BALSTILIMAB (AGEN2034) On Viral Clearance In HPV-Positive Oropharyngeal Cancer Patients With Persistent HPV Detection In plasma cfDNA after definitive therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Balstilimab
Description
This study aims to leverage this unique property of HPV+ OPC to detect possible minimal residual disease represented by persistent viral detection after the completion of definitive treatment. The study will offer adjuvant immune therapy to patients with persistent viral detection and evaluate the clearance of viral load. It will evaluate the rate of viral clearance with immune therapy and establish the link between viral clearance and long-term disease control.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HPV, Oropharyngeal Cancer
Study phase:
Phase II
Physician name:
Luana Guimaraes De Sousa
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-897-9044
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.